Have you heard the news? PARx Solutions has won the eyeforpharma by Reuters Events 2020 Entrepreneur Award in the Health Solution category! We are honored to be in the company of the winners in other categories who are making innovation visible, setting the bar higher and broadening the possibilities for pharma by showing what can be achieved.
Thank you to eyeforpharma for selecting PARx Solutions as a finalist for this year’s eyeforpharma Awards in the Entrepreneur Award: Health Solution category! We are honored to be included in this category, which recognizes work that serves patients and/or health professionals in a beneficial way.
Pharmaceutical Executive | Dan Rubin | September 21, 2018
Pharma brands invest heavily in sales and marketing tactics aimed at convincing physicians to prescribe their product. Even when successful, these efforts represent only a first step in realizing more prescriptions that actually get dispensed. Particularly when a prescription requires prior authorization (PA), retail pharmacy data shows that the originally prescribed product ends up being dispensed less than thirty percent of the time. In two-thirds of cases, the medication is either switched to another product or abandoned altogether, leaving both patients and physicians frustrated. PA requirements are being implemented by payers for more brands across most therapeutic categories, so the negative impact on pharma continues to deepen. Read the full article
Pharmaceutical Executive | Dan Rubin | March 28, 2018
For many pharmaceutical brands, managed care restrictions put tremendous pressure on the ability for patients to access prescribed medications, even when their physicians deem a particular medication to be best suited to treat their condition. To combat this challenge, many brands have engaged third parties to implement programs designed to assist physician practices with managing the cumbersome prior authorization (PA) process. While these programs may help generate higher PA approval rates, this metric alone is insufficient in evaluating whether the program is truly beneficial to patients and impactful for the sponsoring brand. Read the full article